Crinetics Pharmaceuticals (CRNX) Net Cash Flow (2017 - 2026)

Crinetics Pharmaceuticals' Net Cash Flow history runs 10 years deep, the most recent figure standing at $12.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 107.54% year-over-year to $12.8 million; the TTM figure through Mar 2026 stood at $19.4 million (up 106.43% YoY), while the FY2025 annual figure was -$163.4 million, down 177.94% from the prior year.
• Net Cash Flow was $12.8 million for Q1 2026 at Crinetics Pharmaceuticals, up from -$9.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $341.0 million in Q1 2024 to a low of -$170.0 million in Q1 2025.
• Historically, Net Cash Flow has averaged -$5.1 million across 5 years, with a median of -$9.8 million in 2025.
• Biggest YoY gain for Net Cash Flow was 3902.19% in 2024; the steepest drop was 5613.71% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $1.8 million in 2022, then slumped by 5091.37% to -$87.9 million in 2023, then jumped by 40.02% to -$52.7 million in 2024, then surged by 81.49% to -$9.8 million in 2025, then surged by 231.29% to $12.8 million in 2026.
• The last three Net Cash Flow figures came in at $12.8 million (Q1 2026), -$9.8 million (Q4 2025), and $57.2 million (Q3 2025), per Business Quant data.